GlassScriptPhysician profile
Sushma Nakka
NPI 1871787036
$57,180.91
in general payments reported to CMS, 2019-2025
45 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,713 · 2020: $1,873 · 2021: $16K · 2022: $297 · 2023: $8,210 · 2024: $12K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Consulting Fee: $8,750 · Travel and Lodging: $4,098 · Food and Beverage: $1,974 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,370.66 |
| Consulting Fee | $8,750.00 |
| Travel and Lodging | $4,098.42 |
| Food and Beverage | $1,973.61 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $36,476.71 | 2020-2025 | |
| Celgene Corporation | $5,103.37 | 2019-2025 | Reblozyl |
| Janssen Biotech, INC. | $2,934.15 | 2019-2024 | Rybrevant, Tecvayli |
| Glaxosmithkline, LLC. | $2,854.44 | 2021-2025 | Ojjaara |
| Taiho Oncology, INC. | $2,501.59 | 2021-2025 | |
| Beigene, LTD. | $2,250.00 | 2021 | |
| Karyopharm Therapeutics INC. | $1,550.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $898.64 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $315.75 | 2019-2025 | |
| Astellas Pharma US INC | $240.67 | 2020-2025 | Vyloy |
| Daiichi Sankyo INC. | $200.03 | 2022-2025 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $192.21 | 2019-2022 | |
| Dova Pharmaceuticals | $151.68 | 2019-2021 | |
| Genentech USA, INC. | $151.04 | 2020-2025 | Phesgo, Tecentriq, Kadcyla |
| Abbvie INC. | $148.73 | 2020-2025 |
Show all 43 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sushma Nakka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.